These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10824038)

  • 1. Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection.
    Berry V; Page R; Satterfield J; Singley C; Straub R; Woodnutt G
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():87-93. PubMed ID: 10824038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection.
    Berry V; Page R; Satterfield J; Singley C; Straub R; Woodnutt G
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():79-85. PubMed ID: 10824037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Fernandes PB; Chu DT; Bower RR; Jarvis KP; Ramer NR; Shipkowitz N
    Antimicrob Agents Chemother; 1986 Feb; 29(2):201-8. PubMed ID: 3521473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of gemifloxacin.
    King A; May J; French G; Phillips I
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of gemifloxacin compared with other antimicrobial agents against recent clinical isolates of streptococci.
    Ieven M; Goossens W; De Wit S; Goossens H
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():51-3. PubMed ID: 10824033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
    Rittenhouse S; McCloskey L; Broskey J; Niconovich N; Jakielaszek C; Poupard J; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():23-7. PubMed ID: 10824028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemifloxacin.
    Lowe MN; Lamb HM
    Drugs; 2000 May; 59(5):1137-47; discussion 1148. PubMed ID: 10852645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
    Dubois J; St-Pierre C
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():41-6. PubMed ID: 10824031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
    Ernst ME; Ernst EJ; Klepser ME
    Am J Health Syst Pharm; 1997 Nov; 54(22):2569-84. PubMed ID: 9397218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
    Yong DE; Cheong HJ; Kim YS; Park YJ; Kim WJ; Woo JH; Lee KW; Kang MW; Choo YS
    J Korean Med Sci; 2002 Dec; 17(6):737-42. PubMed ID: 12482994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P; Mandell L; Patou G; Dankner W; Tillotson G
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bactericidal activity of gemifloxacin (SB-265805).
    Morrissey I; Clark S; Mathias I
    J Med Microbiol; 2000 Sep; 49(9):841-844. PubMed ID: 10966234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
    Gargallo D; Moros M; Coll R; Esteve M; Parés J; Xicota MA; Guinea J
    Antimicrob Agents Chemother; 1988 May; 32(5):636-41. PubMed ID: 3134844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas.
    Jones RN; Pfaller MA; Erwin ME
    Int J Antimicrob Agents; 2000 Aug; 15(3):227-30. PubMed ID: 10926446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial activity and pharmacodynamics of new quinolones.
    Dalhoff A; Schmitz FJ
    Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
    Wu X; Jiang H; Xu Y; Yue W; Yang L; Song Z; Chen H; Liu T
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):420-7. PubMed ID: 22360669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1999 Jan; 43(1):77-84. PubMed ID: 9869569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.